Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing neurological therapeutics, announced it will present and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Investor Conference scheduled for May 20-21, 2026. The company’s presentation is set for 3:15 p.m. ET on May 21, 2026, with additional virtual meetings throughout the event. This participation provides a platform for Oragenics to update the investment community on its lead candidate, ONP-002, a potential first-in-class treatment for concussion and mild traumatic brain injury (mTBI).
The announcement underscores Oragenics’ strategic focus on advancing ONP-002 through proprietary intranasal delivery technology designed to target the brain directly. The company is working to commence clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. This development is significant given the high unmet medical need in concussion and mTBI, conditions that affect millions annually and lack FDA-approved pharmacological treatments. Oragenics’ intranasal platform could also be applicable to other neurological disorders, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders, broadening its potential impact.
The Sidoti conference, a well-known event for micro-cap companies, offers Oragenics an opportunity to attract investor interest and potentially secure funding to advance its pipeline. For more details, the full press release is available at https://ibn.fm/MLd0Y. Additional company updates can be found in the newsroom at https://ibn.fm/OGEN.
Oragenics’ presentation comes at a critical time as the company transitions from preclinical to clinical development. The ability to secure positive trial results could position ONP-002 as a first-in-class therapy, addressing a market with few effective options. The company’s technology leverages intranasal delivery to bypass the blood-brain barrier, potentially enhancing drug efficacy and reducing side effects. This approach has attracted attention from investors and researchers alike, given its versatility across multiple CNS conditions.
For investors, the Sidoti conference represents a key venue to evaluate Oragenics’ progress and management’s strategy. The one-on-one meetings allow for in-depth discussions about the company’s clinical plans, regulatory pathway, and commercialization prospects. As Oragenics prepares for its Australian trials, the outcome of these discussions could influence near-term stock performance and long-term value creation. The company remains committed to developing innovative therapies for significant neurological unmet needs, as detailed on its website at oragenics.com.
